Marvin is an associate in our New York office and a member of the private funds and secondaries team. His practice focuses on fund formation and secondaries transactions. He represents alternative asset managers and their investors on a variety of corporate, transactional and commercial matters, including fund structuring and investment strategy. He advises clients with fund formation, sponsor- and investor-led secondaries, and securities law compliance matters. Marvin also has experience representing portfolio companies of private capital managers in connection with M&A matters. Prior to joining full-time, Marvin interned at Freshfields where he worked with the global transactions practice group on a variety of private and public market transactions. He is fluent in German and English.
- Southern Cross Management in connection with a GP-led secondary sale transaction of its Fund V portfolio.
- CVC on its $925m global carve-out acquisition of Therakos from Mallinckrodt (awarded IFLR Private Equity Deal of the Year 2025).
- A leading secondaries investment firm on the buy-side in its acquisition of a portfolio of private fund LP totaling over $500m from an institutional investor.
- An institutional investment manager in connection with its primary investment and co-investment activities across private equity and venture capital investment vehicles.
- AstraZeneca on its $1.2bn acquisition of Gracell Biotechnologies Inc.
- KfW IPEX-Bank in connection with the $1.2bn financing for the construction, startup, operation and maintenance of a world-scale anhydrous ammonia plant in Mexico.
- CVC on its strategic partnership with the Women’s Tennis Association.
- Ericsson on the sale of its IoT Accelerator and Connected Vehicle Cloud businesses and related assets to Aeris Communications, Inc.
- Alpek Polyester on its acquisition of OCTAL (a major producer of PET sheet and resin globally).
3 World Trade Center
175 Greenwich Street, 51st Floor